Danish bank cuts Genmab price target, retains "buy" recommendation

Jyske Bank has adjusted its valuation of Genmab’s share price target to DKK 2850 (USD 434.4). Investors should continue to buy, the Danish bank says.

Photo: Stine Tidsvilde

Danish bank Jyske bank has cut Genmab’s share price target by 4 percent, going from DKK 2975 (USD 453.5) to DKK 2850 (USD 434.4). The bank retains its recommendation ”buy” despite the company’s recent dip on the exchange, according to an analysis prior to the company’s financial report, which will be publicized on February 16.

”Fears of increasing rates have hit the Genmab stock hard in 2022, which is down by 13 percent. We regard this as a clear opportunity to buy, as the dip is purely related to the market – small fluctuations in the market sentiment (less interest rate focus) will benefit the Genmab stock,” writes Senior Analyst, Equity Research at Jyske Bank Henrik Hallengreen Laustsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs